Delivery Order SPE2DB22D2214-SPE2DB25FS6QL
Award Date 9/22/25
Potential Completion Date 9/23/25
Potential Value $90K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a $273,806 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing...
- The Defense Logistics Agency awarded a delivery order valued at $50,548.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 26, 2025, with an ultimate completion date of September 29, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B infection. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a delivery order valued at $8,424.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 2, 2025, with completion expected by September 3, 2025. This delivery order represents a firm fixed-price contract with no set-aside designation, awarded through competitive procurement. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency awarded a delivery order valued at $127,248.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 12, 2025, with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization in adults. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 11, 2025, with completion expected by September 12, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and will be performed at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and older,...
- The Defense Logistics Agency awarded a delivery order valued at $3,369.92 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on August 13, 2025, with an ultimate completion date of August 14, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 years and older. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,605.90 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with ultimate completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $7,333.24 on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults 18 years of age and older, representing a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $44,610.31 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 6, 2025, with completion scheduled for August 7, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award leverages AmerisourceBergen's position as a major pharmaceutical distributor and serves the federal medical supply chain, with performance taking place at the company's headquarters...